Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials

Figures & data

Figure 1. Study selection process for the meta-analysis.

Table 1. The basic characteristics of the 14 RCTs.

Author/year	Groups	Sample size	Age (median or mean or range)	Sex (male/female)	Course of disease (mean or range)	Course of treatment	Intervention	Outcomes
Li et al., 2015	EP	70	19-57	31/39	3 months-2 years	1 month	A + C	abcefg
	CG	70	20-55	30/40	3 months-2 years	1 month	A
Zhang, 2015	EP	46	Unknown	29/17	2 months-9 years	4 weeks	A + D	abg
	CG	38	Unknown	20/18	2 months-9 years	4 weeks	A
Sun, 2016	EP	55	20-68	30/25	2 months-2 years	1 month	A + C	aef
	CG	55	18-65	28/27	1 months-2 years	1 month	A
Ying and Shi, 2017	EP	40	22-52	25/15	Unknown	4 weeks	A + D	abcdefg
	CG	40	21-53	24/16	Unknown	4 weeks	A
Fan, 2017	EP	45	18-66	24/21	40 days-15 months	4 weeks	A + C	abg
	CG	45	17-67	23/22	39 days-15 months	4 weeks	A
Zeng et al., 2017	EP	90	18-74	44/46	3 months-4.4 years	4 weeks	B + C	bcdefg
	CG	90	18-72	45/45	3 months-4.3 years	4 weeks	B
Zang, 2017	EP	55	17-60	Unknown	6 months-10 years	1 month	A + C	acg
	CG	55	17-60	Unknown	6 months-10 years	1 month	A
Qian, 2017	EP	60	36.23 ± 6.75	30/30	(1.62 ± 0.38) years	1 month	A + C	acefg
	CG	60	36.94 ± 4.53	31/29	(1.82 ± 0.45) years	1 month	A
Hang, 2018	EP	51	18-67	Unknown	2 months-2 years	4 weeks	A + D	abg
	CG	51	18-67	Unknown	2 months-2 years	4 weeks	A
Duan, 2018	EP	63	36.7 ± 11.4	29/34	(14.6 ± 4.5) years	1 month	A + C	acg
	CG	62	35.8 ± 10.9	24/38	(15.1 ± 4.2) years	1 month	A
Sheng et al., 2018	EP	35	18-64	15/20	2 months-3 years	4 weeks	A + E	cef
	CG	35	18-63	14/21	2 months-3 years	4 weeks	A
Deng, 2019	EP	45	25-49	Unknown	1.8-7.6 years	30 days	A + C	acef
	CG	45	25-49	Unknown	1.8-7.6 years	30 days	A
Gou, 2019	EP	41	27-66	16/25	3 months-6 years	4 weeks	A + E	ag
	CG	41	29-68	17/24	4 months-5 years	4 weeks	A
Peng, 2019	EP	59	32 ± 2.09	22/37	6 weeks-33 months	4 weeks	A + D	abg
	CG	59	31 ± 2.12	28/31	6 weeks-34 months	4 weeks	A

EP: experimental group; CG: control group; A. desloratadine: 5 mg po qd; B. desloratadine: 8.8 mg po qd; C. compound glycyrrhizin tablets:75 mg po tid; D. compound glycyrrhizin tablets: 50 mg po tid; E. compound glycyrrhizin capsule po tid; a. total effective rate; b. adverse reaction; c. recurrence rate; d. serum IgE level; e. CD4+; f. CD8+; g. cure rate.

Figure 2. Risk of bias graph.

Figure 3. Risk of bias summary.

Figure 4. Total response rate.

Figure 5. Cure rate.

Figure 6. Recurrence rate.

Figure 7. Rates of adverse reactions.

Figure 8. Serum total IgE level.

Figure 9. The level of CD4+ T cells.

Figure 10. The level of CD8+ T cells.

Figure 11. The funnel plot of the publication bias.

Li GB, Xue QD, Tang QP. 2015. Clinical observation of desloratadine combined with compound glycyrrhizin in the treatment of chronic urticaria. J Med Res. 44 (1):150–153.

 Google Scholar

Zhang YQ. 2015. Efficacy observation of desloratadine combined with compound glycyrrhizin capsule in the treatment of chronic urticaria. Med Inform. 29(5):287–288.

 Google Scholar

Sun JW. 2016. Clinical effect analysis of desloratadine combined with compound glycyrrhizin in the treatment of chronic urticaria. World Latest Med Inform Dig. 16(35):33–34.

 Google Scholar

Ying MX, Shi L. 2017. Effects of compound glycyrrhizin on chronic urticaria and its effect on T cell subgroup, IgE and EOS in peripheral blood. Chin J Rural Med Pharm. 24(6):34–35.

 Google Scholar

Fan C. 2017. Clinical observation of compound glycyrrhizin combined with desloratadine in the treatment of chronic urticaria. J Frontiers of Med. 7(12):11–12.

 Google Scholar

Zeng DW, Wu WJ, Huang BZ, Chen YF, Xie ZH. 2017. Feasibility analysis of compound glycyrrhizin assisted desloratadine in the treatment of chronic urticaria. Chin Mod Med. 24(20):39–41.

 Google Scholar

Zang YQ. 2017. Clinical observation of desloratadine combined with compound glycyrrhizin in the treatment of chronic urticaria. J Jilin Med. 38(2):366–367.

 Google Scholar

Qian WW. 2017. Clinical study of combination of desloratadine and compound glycyrrhizin in the treatment of chronic urticaria. J Clin Med. 4:13204–13205.

 Google Scholar

Hang Y. 2018. Compound glycyrrhizin capsules combined with desloratadine tablets in the treatment of 102 cases of chronic measles. Health Must-Read Mag. 26(18):16–17.

 Google Scholar

Duan YH. 2018. Effect of compound glycyrrhizin combined with desloratadine in the treatment of chronic urticaria. Health Guide. 17(22):371.

 Google Scholar

Sheng GH, Sun AM, Yin MD, Zhu JY. 2018. Clinical efficacy of desloratadine combined with compound glycyrrhizin on patients with chronic urticaria and its effect on immune function improvement. J anti-Infective Pharm. 15(9):1603–1605.

 Google Scholar

Deng JP. 2019. Clinical effect of desloratadine combined with compound glycyrrhizin on chronic urticaria. Modern Health Maint. 13:112–113.

 Google Scholar

Gou TT. 2019. Clinical efficacy observation of desloratadine dispersible tablets combined with compound glycyrrhizin capsule in the treatment of chronic urticaria. J Big Health. 5:154–155.

 Google Scholar

Peng XG. 2019. Efficacy of compound glycyrrhizin combined with desloratadine in the treatment of chronic urticaria. J Spec Health. 8(21):92.

 Google Scholar